US-based biotechnology firm Rallybio has entered into a strategic alliance with AbCellera to discover, develop, and commercialise new antibody-based therapeutics for rare diseases.
Gene editing company iECURE has raised $65m in a Series A-1 financing round to advance in vivo programmes to treat rare paediatric liver diseases.
Harbour BioMed’s wholly owned subsidiary Nona Biosciences and global biotechnology firm ModernaTX have entered into a license and collaboration deal for the development of immunotherapies.
Navrogen has signed a cooperative research and development agreement (CRADA) with the US National Cancer Institute (NCI) researchers for the clinical development of NAV-001.
Amgen has reported positive end-of-treatment data from the Phase II OCEAN(a)-DOSE study of its investigational olpasiran (formerly AMG 890).
PharmaTher and Case Western Reserve University (CWRU) have entered into an evaluation and exclusive option agreement for the development and commercialisation of ketamine to treat Rett Syndrome.
EpiVax is joining Intravacc and Coalition for Epidemic Preparedness Innovations (CEPI) on a new project to develop universal vaccines for betacoronaviruses, including SARS-CoV-2.
Private biotech firm Ariceum Therapeutics has entered into a strategic partnership deal with AmbioPharm to produce and supply peptide conjugates.
Biotechnology company Normunity has raised $65m in Series A financing round for expanding the frontier of precision immuno-oncology with immune normaliser therapies.
The US Food and Drug Administration (FDA) has granted priority review for Daiichi Sankyo’s quizartinib along with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy to treat newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.